Editors:
- The first single source on this subject to put all this evidence together in a concise and easy to understand manner.
- Uniquely formatted with sidebars, special interest boxes and illustrations.
- Provides a collection of ingeniously organized, up-to-date authoritative chapters divided into five sections.
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (54 chapters)
-
Front Matter
-
Basic Principles and Methods
-
Front Matter
-
-
Major Cell Signaling Pathways
-
Front Matter
-
About this book
This book provides a collection of ingeniously organized, well-illustrated and up-to-date authoritative chapters divided into five sections that are clear and easy to understand. Section one provides an overview of biomarkers, introduces the basic terminologies, definitions, technologies, tools and concepts associated with this subject in the form of illustrations/graphics, photographs and concise texts. Several recent biomarker endeavors that have been initiated and funded by the National Cancer Institute, National Institutes of Health, FDA and other International organizations are presented. Section two involves the signaling pathways controlling cell growth and differentiation altered in cancer. This section analyzes how predictive biomarkers are altered (expressed or amplified) across cancer types. Section three explores how predictive biomarkers play a role in patient stratification and tailored treatment in relationship to specific cancers. In addition, it includes discussion on the various precision medicine initiatives that are going on across the globe (e.g. TARGET, NCI-MATCH, BATTLE, SHIVA, etc.). Section four discusses: (a) how pharmaceutical companies validate predictive biomarker assays and accompanying companion diagnostics either internally or externally with partner companies such as central laboratories or clinical research organizations, and (b) how predictive biomarker tests fall under the oversight of US FDA, Centers for Medicare & Medicaid Services (CMS) and state laws. Section five wraps up novel agents and targets that are being used as targets for cancer therapeutics. The biomarkers associated with these protocols will also be presented. Throughout the book, sidebars, special interest boxes and illustrations are used to explain terms that are either newly introduced, uncommon, or specialized.
Predictive Biomarkers in Oncology will serve as a definitive guide for practicing pathologists, oncologists, basic researchers, and personnel in the pharmaceutical or diagnostic industry interested in learning how “predictive biomarkers” are used in precision cancer therapy.
Editors and Affiliations
-
Department of Pathology and Lab Medicine, Indiana University School of Medicine, Indianapolis, USA
Sunil Badve
-
Targos Inc., Issaquah, USA
George Louis Kumar
About the editors
Indiana University School of Medicine
Indianapolis, IN
USA
George Kumar
Targos Inc.
Issaquah, WA
USA
Bibliographic Information
Book Title: Predictive Biomarkers in Oncology
Book Subtitle: Applications in Precision Medicine
Editors: Sunil Badve, George Louis Kumar
DOI: https://doi.org/10.1007/978-3-319-95228-4
Publisher: Springer Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Nature Switzerland AG 2019
Hardcover ISBN: 978-3-319-95227-7Published: 20 December 2018
eBook ISBN: 978-3-319-95228-4Published: 06 December 2018
Edition Number: 1
Number of Pages: XXI, 642
Number of Illustrations: 3 b/w illustrations, 153 illustrations in colour